Kynd Revenue and Competitors
Estimated Revenue & Valuation
- Kynd's estimated annual revenue is currently $2.8M per year.
- Kynd's estimated revenue per employee is $135,333
Employee Data
- Kynd has 21 Employees.
- Kynd grew their employee count by -22% last year.
Kynd's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Product Manager | Reveal Email/Phone |
2 | Support Specialist | Reveal Email/Phone |
Kynd Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $57.6M | 318 | 24% | N/A | N/A |
#2 | $44.6M | 286 | 23% | $25.4M | N/A |
#3 | $5.1M | 44 | -6% | N/A | N/A |
#4 | $35.1M | 225 | -3% | $46.9M | N/A |
#5 | $14.5M | 100 | 4% | N/A | N/A |
#6 | $1.3M | 15 | -6% | N/A | N/A |
#7 | $1.5M | 15 | -6% | N/A | N/A |
#8 | $2.9M | 29 | -12% | N/A | N/A |
#9 | $125.2M | 691 | 6% | N/A | N/A |
#10 | $95.9M | 529 | -1% | N/A | N/A |
What Is Kynd?
The simple way to find and book #NDIS support.
keywords:N/AN/A
Total Funding
21
Number of Employees
$2.8M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kynd News
A batch of anti-anxiety medication has been recalled by Australia's peak medical regulatory body following reports of unexpected allergic...
A batch of anti-anxiety medication has been recalled by Australia's peak medical regulatory body following reports of unexpected allergic...
The allergic reaction symptoms to watch out for include a rash, tingling or burning skin, skin redness or itching, and swelling of the...
The allergic reaction symptoms to watch out for include a rash, tingling or burning skin, skin redness or itching, and swelling of the...
Sales of Kynd began this week across Liberty's 45-dispensary footprint. The initial launch includes six strain offerings, namely Blueberry...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.6M | 22 | -37% | N/A |
#2 | $4.9M | 25 | 4% | N/A |
#3 | $2.9M | 25 | 4% | N/A |
#4 | $4.3M | 33 | -8% | N/A |
#5 | $5.7M | 35 | -24% | N/A |